![]() |
市場調查報告書
商品編碼
1402415
血漿衍生治療市場- 副產品(免疫球蛋白、凝血因子、白蛋白)、應用(血友病、原發性免疫缺陷病、特發性/免疫性血小板減少性紫斑症(ITP))、全球預測,2023 -2032 年Plasma Derived Therapy Market - By Product (Immunoglobulins, Coagulation Factors, Albumin), Application (Hemophilia, Primary Immunodeficiency Diseases, Idiopathic/Immune Thrombocytopenic Purpura (ITP)), Global Forecast, 2023-2032 |
由於血漿採集中心和製造設施網路不斷擴大,2023 年至 2032 年間,全球血漿衍生治療市場將以 7.5% 的CAGR成長。這些基礎設施的不斷成長滿足了對血漿衍生療法不斷成長的需求。隨著血漿可及性的增加,市場上治療產品的生產不斷增加,確保了更穩健的供應鏈。此次擴張將在滿足全球對血漿衍生療法不斷成長的需求方面發揮關鍵作用,並將為市場的整體發展做出重大貢獻。
例如,2023 年,日本生物製藥公司武田製藥 (Takeda Pharmaceutical) 正在大阪建造日本最大的最先進設施,用於生產血漿衍生療法 (PDT)。這項策略性舉措增強了武田的製造和供應能力,滿足全球對 PDT 不斷成長的需求,並滿足日本及其他地區不斷成長的患者需求。此舉標誌著武田為加強血漿衍生治療市場、增強生產能力以滿足全球需求以及滿足日益成長的患者需求做出了重大貢獻。
血漿衍生治療產業根據產品、應用和地區而分散。
受白蛋白在各種醫療干預措施中的多功能應用和重要作用的推動,白蛋白細分市場將在 2032 年建立重要的市場立足點。作為一種重要的血漿蛋白,具有廣泛的治療用途,包括重症監護、手術和創傷,白蛋白將因其不可或缺的價值而脫穎而出。隨著對白蛋白療法的需求不斷成長,該細分市場將在塑造血漿衍生療法行業前景方面發揮關鍵作用。
血漿衍生療法的特發性/免疫性血小板減少性紫斑症 (ITP) 市場規模將在 2032 年大幅成長,這歸因於 ITP 發病率的不斷上升以及人們日益認知到血漿衍生療法作為有效干預措施。隨著人們越來越關注解決自體免疫疾病,特別是 ITP,對有針對性和可靠的治療方法的需求正在上升。醫學研究和治療創新的不斷進步將進一步將 ITP 領域定位為血漿衍生療法不斷擴大的領域的關鍵貢獻者,滿足關鍵的醫療保健需求。
由於其先進的醫療基礎設施和強大的研發工作,歐洲將在 2023 年和 2032 年實現顯著的CAGR。血漿相關疾病盛行率的上升加劇了這一趨勢。歐洲的醫療保健格局以技術進步和對醫療創新的承諾為標誌,凸顯了其在塑造血漿衍生治療行業發展軌跡方面的關鍵作用,使其成為該行業成長和發展的主要貢獻者。
Global Plasma Derived Therapy Market will grow at a 7.5% CAGR between 2023 and 2032, owing to the expanding network of plasma collection centers and manufacturing facilities. The continuous growth of these infrastructure elements addresses the escalating demand for plasma-derived therapies. With increased accessibility to plasma, the market experiences a boost in the production of therapeutic products, ensuring a more robust supply chain. This expansion will play a pivotal role in meeting the growing global demand for plasma-derived therapies and will significantly contribute to the market's overall development.
For instance, in 2023, Takeda Pharmaceutical, a Japanese biopharmaceutical company, is constructing a state-of-the-art facility in Osaka, the largest of its kind in Japan, to manufacture plasma-derived therapies (PDTs). This strategic initiative enhances Takeda's manufacturing and supply capabilities, meeting the growing global demand for PDTs and addressing increased patient needs in Japan and beyond. This move marks Takeda's significant contribution to strengthening the plasma-derived therapy market, augmenting production capabilities to meet global demand, and addressing increasing patient needs.
The plasma derived therapy industry is fragmented based on product, application, and region.
The albumin segment will establish a significant market foothold by 2032, fueled by the versatile applications and essential role of albumin in various medical interventions. As a crucial plasma protein with widespread therapeutic uses, including in critical care, surgery, and trauma, albumin will stand out for its indispensable value. With a rising demand for albumin-based therapies, this segment will play a pivotal role in shaping the plasma derived therapy industry outlook.
The plasma derived therapy market size idiopathic/immune thrombocytopenic purpura (ITP) segment will witness substantial growth through 2032, attributed to the escalating incidence of ITP and the growing recognition of plasma-derived therapies as effective interventions. With an increasing focus on addressing autoimmune disorders, particularly ITP, the demand for targeted and reliable therapies is rising. Ongoing advancements in medical research and therapeutic innovation will further position the ITP segment as a key contributor to the expanding landscape of plasma-derived therapies, addressing critical healthcare needs.
Europe will register a notable CAGR during 2023 and 2032 due to its advanced healthcare infrastructure and robust research and development efforts. The rising prevalence of plasma-related disorders adds momentum to this trend. Europe's healthcare landscape, marked by technological advancements and a commitment to medical innovation, underscores its pivotal role in shaping the trajectory of the plasma derived therapy industry, making it a primary contributor to the industry growth and development.